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Edited by Gerrit van MeerAbstract Mammalian epidermis produces and delivers large
quantities of glucosylceramide and sphingomyelin precursors to
stratum corneum extracellular domains, where they are hydro-
lyzed to corresponding ceramide species. This cycle of lipid pre-
cursor formation and subsequent hydrolysis represents a
mechanism that protects the epidermis against potentially harm-
ful eﬀects of ceramide accumulation within nucleated cell layers.
Prominent skin disorders, such as psoriasis and atopic dermati-
tis, have diminished epidermal ceramide levels, reﬂecting altered
sphingolipid metabolism, that may contribute to disease severity/
progression. Enzymatic processes in the hydrolysis of glucosyl-
ceramide and sphingomyelin, and the roles of sphingolipids in
skin diseases, are the focus of this review.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Mammalian skin is composed of two distinct layers divided
by a basement membrane zone: (1) the underlying dermis con-
taining primarily ﬁbroblasts embedded in an acellular colla-
gen/elastin matrix that accounts for the majority of skin
thickness; and (2) the overlying epidermis, responsible for for-Abbreviations: Cer, ceramide; CLE, corneocyte lipid envelope (cova-
lently-bound omega-hydroxy ceramides); FA, fatty acid; GlcCer,
glucosylceramide; GlcCerase, b-glucocerebrosidase; SC, stratum cor-
neum; SM, sphingomyelin; SMase, sphingomyelinase; N, non-hydroxy
fatty acid; A, alpha-hydroxy fatty acid; O, omega-hydroxy fatty acid;
E, esteriﬁed (omega) fatty acid; S, sphingosine base; P, phytosphin-
gosine base; H, 6-hydroxy-sphingosine base
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and penetration of xenobiotics. The function of this barrier re-
sides primarily in the extracellular lipid domains between the
outermost, enucleated cells, called corneocytes, of the stratum
corneum (SC). Mammalian SC contains extensive quantities of
lipids, localized to these extracellular domains (interstices),
comprised of nearly equimolar quantities of ceramides (Cer),
cholesterol, and free fatty acids, a ratio that is imperative for
normal organization into the lamellar membrane structures
primarily responsible for epidermal barrier homeostasis [1,2].
Cer species comprise approximately half of the total intercellu-
lar lipid content by weight, and are critical for these lamellar
membrane structures [3,4]. The speciﬁc roles for Cer in epider-
mal function have been revealed in studies with both normal
and diseased human skin, as well as animal models and model
membranes in vitro [5,6]. For example, the Cer content is al-
tered in patients with both atopic dermatitis [7–9] and psoriasis
[10,11] (discussed further below). Likewise, cholesterol as well
as both essential and non-essential free fatty acids play sepa-
rate, critical roles in epidermal barrier homeostasis.
Given that human SC contains at least nine major Cer frac-
tions (see Fig. 1), many of which are unique to the epidermis,
including omega(x)-hydroxylated and x-acylated forms, as
well as x-hydroxy-Cer species that are covalently attached
via the x-hydroxyl of the N-acyl fatty acid to corniﬁed enve-
lope proteins of the enucleate stratum corneum cells (i.e., cor-
neocytes), the metabolism of these unique sphingolipids is of
signiﬁcant interest. It is intriguing that mammalian epidermis
forms these and other barrier lipids as precursor species, stor-
ing them with other lipid precursors in membrane-limited
organelles, called lamellar bodies (LBs), a process that requires
at least one transport protein [12]. It is only following the fu-
sion of these LBs with the apical plasma membrane of the out-
ermost nucleated cell layer of the epidermis, the stratum
granulosum, that their combined lipid and protein contents
are secreted [13]. The subsequent hydrolysis of these lipid pre-
cursors constitutes the ﬁnal ’processing’ step that facilitates
eﬀective permeability barrier formation in the SC. Since the
myriad Cer species in mammalian SC are generated nearly
exclusively from glucosylceramide (GlcCer) and sphingomy-
elin (SM) precursors, this review focuses on the metabolism
of these unique sphingolipids, as well as on the changes in
the content of these lipids associated with common skin disor-
ders such as atopic dermatitis and psoriasis.ation of European Biochemical Societies.
Fig. 1. Structures of major human stratum corneum (SC) ceramide species. Sphingoid base structures include sphing-4-enine (sphingosine), 4-
hydroxysphinganine (phytosphingosine), and sphing-[6-hydroxy]-4-enine (6-OH-sphingosine) bases. Cer 1, Cer 4, and Cer 9 are commonly termed
acyl-ceramides, as they contain linoleic acid esteriﬁed to the omega-hydroxy of the very long chain N-acyl fatty acid. Note that all nine ceramide
species are generated via deglucosylation of the respective glucosylceramide species, while only Cer 2 [NS] and Cer 5 [AS] are generated via hydrolysis
of corresponding sphingomyelin precursors. Abbreviations for Cer species (as per Motta S., et al. [11]): N, non-hydroxy-FA; A, a-hydroxy-FA; O,
omega-hydroxy FA; E, esteriﬁed (omega)-FA; S, sphingosine base; P, phytosphingosine base; H, 6-hydroxy-sphingosine base.
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and subsequent extracellular lipid hydrolysis noted above,
appears to reﬂect a mechanism by which the epidermis can
produce and store very large quantities of Cer, while simulta-
neously protecting itself from potentially adverse intracellular
events that could stem from an excessive accumulation of these
bioactive lipids within the nucleated epidermal cell compart-
ments. Speciﬁcally, various Cer species and metabolites have
well-recognized roles in signaling diﬀerent cell fate outcomes,
such as proliferation, diﬀerentiation, and/or apoptosis depend-
ing on the sphingolipid species involved. In addition, inappro-
priate accumulation of Cer species leads to cell death in
keratinocytes [14–18]. Thus, the sequential formation and
sequestration of Cer precursor lipids, followed by post-secre-tion, extracellular hydrolysis to regenerate free Cer species, al-
lows for the orderly accumulation of these sphingolipids
required for the barrier, while simultaneously minimizing risks
from adverse Cer signaling events.2. Precursors of mammalian stratum corneum ceramides
The synthesis of Cer species, although occurring throughout
the epidermis [19], increases with epidermal diﬀerentiation,
consistent with elevated sphingolipid generation and content
in more-diﬀerentiated epidermal layers [20–22]. During synthe-
sis, the varied Cer species destined for the SC are modiﬁed at
the 1-hydroxy position to either GlcCer species by GlcCer
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GlcT1; EC 2.4.1.80) [23,24], or to sphingomyelin (SM) species
by the transfer of phosphorylcholine from phospatidylcholine
[25,26]. As noted above, although the majority of Cer species
contained within epidermal lamellar bodies (LBs) are glucosy-
lated [27–31], sphingomyelin (SM) species are also present in
substantial quantities [28,29]. Consistent with this, GlcCer syn-
thase activity increases during epidermal diﬀerentiation both
in vitro [32,33] and in vivo [34], and as the permeability barrier
is forming in utero [35]. Moreover, inhibitor studies revealed
that GlcCer synthase activity and the generation of GlcCer
species, are required for normal barrier homeostasis [34]. Bio-
chemical studies show that the increase in Cer levels that
occurs during the ﬁnal stages of mammalian epidermal diﬀer-
entiation corresponds with a decrease in GlcCer and SM, fol-
lowing a peak of these latter sphingolipids in the uppermost
nucleated cell layers, or stratum granulosum (SG) [20–22,36].
These marked shifts in the content of sphingolipid precur-
sors/products have been visualized in normal human epidermis
by immunoelectron microscopy, using antibodies to both Glc-
Cer and Cer [37].
The distinct molecular species of human SC Cer include
three unique omega-hydroxylated Cer [38–41], as noted above
(see Fig. 1). The precursor–product relationship for each of
these SC Cer molecular species has recently been delineated
[42,43]. Analysis of epidermal SM species revealed three major
subfractions with distinctive amide-linked (N-acyl) fatty acid
(FA) composition; i.e., containing either long-chain FA (SM-
1; C(22–26)), shorter-chain FA (SM-2; primarily C16), or
short-chain alpha-hydroxy FA (SM-3; C16–18) [42]. In addi-
tion, these three major epidermal SM species contain either
sphingosine or sphinganine, but they lack phytosphingosine
as the sphingoid base backbone. Thus, only two of the nine
SC Cer species, Cer 2 (NS)1 and Cer 5 (AS) (see Fig. 1), derive
from SM precursors [42].
A comparable analysis of epidermal glucosylceramides (Glc-
Cer) indicates conversely that distinctive epidermal GlcCer
precursors correspond to all Cer species in epidermis and SC
[42,43]. Thus, all nine of the major human SC Cer species,
including the omega(x)-hydroxy fatty-acid-containing Cer spe-
cies; i.e., Cer 1 (EOS), Cer 4 (EOH), and the most-recently de-
scribed Cer 9 (EOP) [41], derive from GlcCer, while only two
Cer species (Cer 2 (NS) and Cer 5 (AS)), also derive in part
from corresponding SM precursors (see Fig. 1). These results
provide further details about sphingolipid processing, and sug-
gest potential divergent roles for GlcCer- vs. SM-derived Cer
species in epidermal structure and function.3. Enzymatic processing of glucosylceramide and sphingomyelin
is required for epidermal barrier function
Although at least two enzymes can catalyze the hydrolysis of
b-linked glucose-moieties, only b-glucocerebrosidase (GlcCer-
ase; EC 3.2.1.45) speciﬁcally hydrolyzes GlcCer-to-Cer. Early
reports described b-glucosidase activity in both whole mam-1 Abbreviations for Cer species to delineate structures (as per Ref.
[11]), containing as follows: N, non-hydroxy-FA; A, a-hydroxy-FA; O,
omega-hydroxy FA; E, esteriﬁed (omega)-FA; S, sphingosine base; P,
phytosphingosine base; H, 6-hydroxy-sphingosine base.malian skin as well as isolated epidermis (reviewed in [44]).
In porcine epidermis, this b-glucosidase activity is active at
acidic pH [45], and the activity in epidermis and palatal epithe-
lium exceeded that in non-keratinized oral epithelium [46].
Thus, the relative inactivity of b-glucosidase in non-keratinized
epithelium is consistent not only with the persistence of GlcCer
species to the epithelial surface [47,48], but also with less-strin-
gent barrier in non-keratinized oral epithelium [49].
The speciﬁcity of the epidermal activity toward GlcCer
substrate(s) was later shown to be a consequence of speciﬁc
GlcCerase activity, with higher activity in the outer, more dif-
ferentiated epidermal cell layers, extending into the enucleate
SC [44,50], with elevated activity evident in serial frozen
sections at the region corresponding to the stratum granulo-
sum-SC transition [51]. Immunohistochemical staining for
GlcCerase protein also revealed enhanced ﬂuorescent signal
in the outer nucleated layers of human epidermis, concentrated
at the apex and margins of SG cells, as well as within extracel-
lular membrane domains of the lower SC [37]. In situ enzyme
zymography with both whole skin and tissue sections revealed
that the highest levels of GlcCerase activity are present in the
upper SG and the lower SC [50,52,53]. Finally, in extracts from
individual epidermal layers, GlcCerase activity is present
throughout murine epidermis, again with the highest activity
in the SC, peaking in the lower-to-mid-SC [44,50]. Thus, the
processing of GlcCer-to-Cer within the outer epidermis is
attributable to retention of speciﬁc enzymatic activity within
extracellular domains of the SC.
The link between GlcCer-to-Cer conversion and normal epi-
dermal permeability barrier homeostasis became evident when
both mRNA and enzyme activity levels for GlcCerase were
found to be increased during the recovery of the barrier follow-
ing acute abrogation in a murine model [54]. In vivo inhibition
of GlcCerase using topical application(s) of bromoconduritol
B-epoxide (BrCBE), a potent and speciﬁc inhibitor for this en-
zyme [55], reduced murine epidermal GlcCerase activity by
>90%, and signiﬁcantly diminished barrier function [54,56],
demonstrating a requirement for this enzymatic processing in
the maintenance of epidermal barrier homeostasis. This func-
tional delay is due to replacement of the normal, highly-
ordered, SC lamellar membrane arrays with disordered linear
arrays of incompletely-processed, immature-appearing mem-
brane structures [56,57]. Additional evidence for the impor-
tance of GlcCer processing in epidermal function was
obtained using a null-allele GlcCerase-deﬁcient mouse [58], a
model that was developed as a murine analogue for Gaucher
disease, and which retains less than 1% residual enzyme activ-
ity. The homozygous GlcCerase-deﬁcient animals displayed
highly-disordered membrane arrays and a corresponding se-
verely-compromised barrier [57]. The proﬁle of SC and epider-
mal lipid contents revealed both increased GlcCer levels, and
diminished Cer, consistent with a deﬁciency of this enzyme.
Interestingly, the epidermis of heterozygous animals, which
retains approximately 50% of normal GlcCerase activity,
revealed none of the lipid biochemical, ultrastructural, or func-
tional abnormalities that were evident in the more-severely
deﬁcient animals [57]. This knockout approach demonstrated
not only the importance of GlcCer-to-Cer conversion for bar-
rier homeostasis, but also that a single GlcCerase gene product
solely accounts for this activity in mammalian epidermis.
Additional murine models that more-closely mirror the
molecular mutations in human Gaucher disease have revealed
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GlcCerase point mutations equivalent to the common muta-
tions found in human Gaucher disease (e.g., L444P) revealed
no neurologic pathology, severe ichthyotic (scaling) and histo-
logic abnormalities were evident in the epidermis [59]. In fact,
these animals do not survive beyond the initial 24 h post-
partum, presumably because of abnormally high water loss
resulting from the epidermal lipid processing defect [59].
Examination of SC ultrastructure (using ruthenium tetrox-
ide-post-ﬁxed samples) from these animals revealed marked
structural abnormalities in the SC membrane lipid domains,
including incompletely processed lamellar body contents
throughout the SC interstices (W. Holleran & R. Proia, unpub-
lished observations), as observed in b-GlcCerase deﬁciency of
genetic or inhibitor-based origin.
Skin samples from human Gaucher patients with severe Glc-
Cerase deﬁciency; i.e., neonatal Type 2 disease, demonstrated
similar SC membrane structural abnormalities [57,60]. Inter-
estingly, Gaucher patients with less-severe disease do not
display signiﬁcant abnormalities in SC ultrastructure [60],
consistent with the normal ﬁndings in mice heterozygous for
GlcCerase deﬁciency described above. Together, these results
suggest that an excess of this enzyme is available in normal epi-
dermis under basal conditions; and conversely, that a minimal
threshold of epidermal enzyme activity, that no longer can
support normal SC lamellar membrane formation and barrier
integrity, exists in severe Gaucher disease with skin involve-
ment. Interestingly, epidermal ultrastructure abnormalities
may help to predict the severity of Gaucher disease, and there-
by assist with diagnostic assessment [61].
Although the studies summarized above were the ﬁrst to
demonstrate the critical requirement for enzymatic hydrolysis
of lipid precursors (GlcCer) to speciﬁc products (Cer) in mam-
malian epidermis, enzymatic processing of sphingomyelin
(SM) to Cer by sphingomyelinase (SMase; EC 3.1.4.12) also
is critical for SC structure and epidermal barrier homeostasis.
At least two isoenzymes in human skin can hydrolyze SM to
Cer, including a lysosomal-type acid-pH optimum sphingo-
myelinase (aSMase) and a non-lysosomal, magnesium-depen-
dent neutral-pH optimum sphingomyelinase (nSMase). The
epidermal aSMase has optimal activity at pH 4.5–5.0, and is
activated by Triton X-100 (0.1% w/v) in vitro [62,63].
Although both the acidic- and neutral-SMase enzymes are in-
volved in the recovery of the epidermal permeability barrier
following an acute challenge [64], a number of ﬁndings reveal
that at an acid-pH, the lysosomal enzyme appears to be pri-
marily responsible for the extracellular hydrolysis of SM-
to-Cer in mammalian SC. For example, aSMase activity in
SC localizes primarily to intercellular membrane domains
[13,65], making it ideally situated to catalyze this critical lipid
processing step. In addition, aSMase activity increases, in
parallel with accumulation of lipids, within lamellar bodies
during the maturation of these critical epidermal organelles
[13]. Furthermore, in normal mice aSMase activity increases
two hours following acute barrier abrogation, an increase
not observed in tumor necrosis factor-receptor (TNF-R)-deﬁ-
cient mouse epidermis that display delayed barrier recovery
[64]. Inhibition of this increase in aSMase activity by two
independent approaches; i.e., a Cer-structural analog, PDHS,
or intracellular inhibiton at the level of the lamellar body with
either imipramine [64] or desipramine [63], signiﬁcantly delays
epidermal barrier recovery following an acute challenge. Thisfunctional delay is accompanied by an increase in SM content,
as well as a reduction of normal extracellular lamellar mem-
brane structures in the SC [63]. Consistent with these observa-
tions, patients with Niemann-Pick (type A) disease,
characterized by a deﬁciency of lysosomal aSMase, demon-
strate abnormal permeability barrier homeostasis, including
delayed recovery kinetics following an acute challenge [63].
Given that the inhibitor-induced delays in barrier recovery
discussed above can be overridden by topical co-applications
of Cer [63], alteration of the Cer-to-SM ratio, rather than
SM accumulation itself, appears to be responsible for the
diminished epidermal barrier function. This latter ﬁnding con-
trasts with the consequences of absent GlcCerase, where accu-
mulation of enzyme substrates (i.e., GlcCers) in the SC, rather
than reduction of enzyme products, is responsible for the
resultant membrane alterations and diminished barrier func-
tion [56].
The contribution of speciﬁc SM precursors to SC Cer species
was further addressed by structural analysis of human epider-
mal SM species (see above) [42]. Given that only two of the
nine known human SC Cer species; i.e., Cer 2 (NS) and Cer
5 (AS) (see Fig. 1), are generated in part by SM hydrolysis,
and that all nine major SC Cer species are derived from GlcCer
precursors [42,43], the GlcCer-to-Cer pathway appears to have
a more-critical role for generating the full spectrum of unique
Cer species that comprise the epidermal barrier. Consistent
with this interpretation is the more-signiﬁcant epidermal bar-
rier dysfunction that is evident with GlcCerase deﬁciency
(i.e., in either severe Gaucher disease or GlcCerase knockout
mice) [57,60] than has so far been observed with aSMase deﬁ-
ciency (i.e., Niemann-Pick disease) [63,64].
The role of nSMase in epidermal structure and function is
less-well resolved. Although aSMase activity appears primarily
responsible for the majority of SM-to-Cer hydrolysis that oc-
curs in the extracellular domains of the SC, nSMase activity
also is involved in epidermal homeostasis. For example, de-
layed barrier recovery following an acute challenge to the skin
of FAN-deﬁcient mice, with FAN being an adapter protein in
TNFR55 signaling, suggests a role for nSMase activity in epi-
dermal barrier recovery and homeostasis [66]. However, de-
layed barrier recovery without the normal increase in
aSMase activity (or changes in nSMase activity), also was
noted in TNF-R-deﬁcient mouse skin [64]. Although these
studies do not distinguish between aSMase and nSMase-
dependent events, they are consistent with the SM-to-Cer con-
version being critical for epidermal barrier homeostasis.
The results summarized above represent strong evidence for
the dynamic events occurring during the ﬁnal stage of epider-
mal/barrier diﬀerentiation and development. As such, it should
now be readily apparent that extracellular lipid processing of
both GlcCer and SM precursors is critical for mammalian epi-
dermal structure and function. Interestingly, the importance of
the gradual decline in epidermal SMase activity [67] for the
decline in barrier function in aging [68] has yet to be fully
explored. Finally, given that SM-to-Cer turnover (and recy-
cling) has been implicated in myriad cellular processes
(reviewed in [69,70]), and that active sphingolipid remodeling
is ongoing within proliferating and more-diﬀerentiated
keratinocytes (Uchida & Holleran; unpublished observations),
it is highly likely that additional important roles will be
revealed for both GlcCer and SM in cutaneous function and
disease.
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requires GlcCer processing
Mammalian SC contains a unique lipid layer that is cova-
lently-attached to the external surface of corniﬁed envelope
proteins of fully-diﬀerentiated corneocytes. This corneocyte
lipid envelope (CLE) primarily consists of omega(x)-OH Cer
covalently attached to highly-crosslinked, corniﬁed envelope
proteins [71] (see Fig. 2). The x-OH group of these Cer is re-
quired for CLE formation [72,73], as this moiety represents
the attachment point between the Cer and speciﬁc amino acids
of corniﬁed envelope proteins, including involucrin and others
[74]. Although puriﬁed transglutaminase 1 enzyme can per-
form this protein ceramidation reaction in vitro [75], whether
this enzyme is solely responsible for this unique reaction
in vivo remains unresolved, as transglutaminase 1-deﬁcient
patient epidermis contains sporadic normal CLE structures
[76], as well as near-normal quantities of covalently-attached
Cer [77].
Similar to the formation of membrane bilayer structures in
the SC described above, lipid processing also is required to
generate the mature CLE structure (Fig. 2). A number of ﬁnd-
ings support this conclusion. First, in epidermis lacking Glc-
Cerase activity, the CLE contains only covalently-attached
x-OH GlcCer species [78,79]. Second, CLE structures also
are evident in Gaucher mouse SC by ultrastructural analysis
(Y. Uchida & W. Holleran, unpublished observations), despite
the parallel accumulation of covalently-attached x-OH GlcCer
and an absence of the corresponding covalently-bound x-OH
Cer species in b-GlcCerase-deﬁcient epidermis [78,79]. Thus,Fig. 2. Formation and secretion of LB at stratum granulosum – stratum cor
sphingomyelin (SM), glycerophospholipids (PL), and cholesterol sulfate (CS)
the epidermis. Lipid packaging into the LB requires function of at least one
limiting membranes of the LB [12]. Fusion of the LB with the apical plasma
(stratum granulosum), allows extrusion of lipid precursors into the extrace
generates the major lipid classes required for epidermal barrier function; i.e
corneocyte lipid envelope (CLE) consists of x-OH-ceramides that are covalen
(CE), and is formed sequentially with the addition of omega-OH-GlcCer fodeglucosylation, though clearly required for lamellar mem-
brane formation/organization [54,56,57], is not required for
initial CLE formation. However, since the covalent attachment
of Cer to corniﬁed envelope proteins involves the x-OH
groups of Cer [73], the (bulky) hydrophilic glucose residue, fac-
ing toward the extracellular domains, could further interfere
with organization of the compact lamellar membranes
required for competent barrier function. Thus, mature CLE
formation occurs in a sequential manner; i.e., attachment of
x-OH GlcCer followed by subsequent enzymatic deglucosyl-
ation by GlcCerase.5. Regulation of GlcCerase activity in the epidermis and stratum
corneum
As noted above, the post-secretory processing of GlcCer pre-
cursors into Cer within the SC interstices is catalyzed by Glc-
Cerase, a lysosomal, acidic-pH optimum enzyme. The activity
of epidermal GlcCerase has been shown to possess an acidic
pH optimum, with peak in vitro activity at pH 5.2, and absent
or signiﬁcantly reduced activity at neutral pH (7.4) [44,45,50].
Given that epidermal barrier homeostasis is perturbed when
the normally-acidic SC is neutralized [52,80], SC acidiﬁcation
appears to have a signiﬁcant role in epidermal function(s),
including lipid processing events. Speciﬁcally, permeability
barrier recovery proceeds normally when barrier-disrupted
murine skin is exposed externally to solutions buﬀered to an
acidic pH [52]. In contrast, the initiation of barrier recovery
slows when barrier-disrupted skin is exposed to a neutralneum interface. Precursor lipids, including glucosylceramide (GlcCer),
, are packaged into lamellar bodies (LB) within the upper cell layers of
ABC transporter protein, ABCA12, which appears to localize to the
membrane (PM) in the uppermost nucleated cell layer of the epidermis
llular domain(s). Subsequent enzymatic processing of precursor lipids
., ceramides (Cer), cholesterol (Chol), and free fatty acids (FFA). The
tly attached to the highly-crosslinked proteins of the corniﬁed envelope
llowed by deglucosylation.
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formation and secretion of LB proceed comparably when skin
is exposed to either acidic (pH 5.5) or neutral (pH 7.4) condi-
tions. However, exposure to pH 7.4 (but not pH 5.5) results in
both the persistence of immature, extracellular lamellar mem-
brane structures accompanied by a marked decrease in the
in situ activity of GlcCerase [52]. Indeed, despite an increased
pH toward neutrality in the lower SC, extracellular microdo-
mains remain acidic [81], strongly suggesting that GlcCerase
could be activated by localized changes in SC pH. Consistent
with the membrane localization of acidic microdomains in
lower SC, increased GlcCerase activity is evident with increas-
ing depth of tape stripping of mammalian skin [50,82]. Finally,
while short-term changes in pH reversibly activate/inactivate
GlcCerase [80], more prolonged elevations in pH ultimately re-
sult in an irreversible loss of enzyme content/activity due to a
serine protease-mediated degradation of GlcCerase [83]. Thus,
extracellular pH in the SC also has an important role in regu-
lating GlcCer-to-Cer processing through enzyme-dependent
hydrolysis.
Additional mechanisms are likely to modulate the post-
translational changes in GlcCerase activity. For example, in
extracutaneous tissues, GlcCerase is activated by small mole-
cular weight glycoproteins, called saposins (SAPs) [84]. In par-
ticular, SAP-A and SAP-C can upregulate GlcCerase activity
in reconstituted, in vitro enzyme systems [85,86]. Four of the
SAP proteins; i.e., SAP-A–SAP-D, each of which is expressed
in human epidermis (Holleran et al., unpublished results), are
derived by proteolytic processing of a common precursor pro-
tein, prosaposin [87]. Given the importance of GlcCerase activ-
ity in mammalian epidermis, it is not surprising that
prosaposin-deﬁcient mice display GlcCer accumulation, sub-
normal levels of Cer, and immature SC lamellar membranes
[78], as in severe Gaucher disease (see above). Furthermore,
the decreased levels of epidermal prosaposin protein [88], also
may explain, in part, the apparent decrease in SMase activities
in patients with atopic dermatitis [89], contributing to the
diminished SC Cer content of these patients (discussed further
below). Finally, the striking abnormality in SC membrane do-
mains in prosaposin-deﬁcient mice is accompanied by an accu-
mulation of GlcCer species that are covalently-attached to
corniﬁed envelope proteins [78], again consistent with deglu-
cosylation of x-OH-GlcCer occurring after covalent attach-
ment to corniﬁed envelope proteins. Together, these results
suggest that extracellular SAP activation of GlcCerase activity
is important for normal SC lipid processing.6. Alterated ABCA12-dependent transport of glucosylceramide
into lamellar bodies in harlequin ichthyosis and lamellar
ichthyosis type 2
The role(s) of lipid transporter proteins in epidermal func-
tion and disease have only recently begun to be addressed. Re-
cent discoveries regarding the genetic causes of speciﬁc
congenital ichthyoses, severe skin disorders characterized by
excessive and debilitating scaling of the SC, highlight the
importance of lipid (and in particular, sphingolipid) transport
in epidermal function. For example, the ABCA12 gene was ini-
tially mapped to a region of chromosome 2q34 that harbors
the genes for lamellar ichthyosis [90]. Subsequently, nine fam-
ilies with the rare autosomal recessive skin disorder, lamellarichthyosis type 2, were shown to have mutations in the
ABCA12 gene [91]. In addition, mutations in the ABCA12 gene
also have been reported in patients with harlequin ichthyosis
(HI) [12,92], the most severe form of congenital ichthosis that
is often fatal in the neonatal period. A recent report conﬁrms
ABCA12 to be a major HI gene [93]. The ABCA12 protein be-
longs to the superfamily of ATP-binding cassette transporter
proteins that require ATP for transport of molecules across
cell membranes [94], and appears to be situated in the limiting
membrane of the epidermal LBs [12].
Abnormal LB formation and secretion has long-been associ-
ated with HI pathogenesis [95,96]. Although the cytosol of
stratum granulosum cells contains an extensive number of
LBs [97], a paucity of these lipid-rich organelles are evident
in HI skin [12,95,96]. Immunoﬂuorescence using an anti-Glc-
Cer antibody [37] revealed diﬀuse GlcCer distribution through-
out the epidermis of HI patient skin, in contrast to the
punctate pattern concentrated at the stratum granulosum level
in normal skin [12], suggesting alterations in the transport of
GlcCer species into the internal membrane structures of the
LB. In addition, HI keratinocytes showed intense GlcCer
staining around nuclei that failed to redistribute to the cell
periphery during calcium-induced diﬀerentiation in vitro,
instead revealing a ‘congested pattern’ of GlcCer distribution
[12]. Importantly, genetic correction of HI keratinocytes with
wild-type ABCA12 normalized the GlcCer distribution pattern
in vitro [12]. Interestingly, HI corneocytes also contained
abnormal lipid droplets that resembled immature LBs, sugges-
tive of entombed lipids within SC cells. The apparent lack of
GlcCer delivery to LB precursors in HI stratum granulosum
cells impairs the formation and maturation of these mem-
brane-bound organelles, and ultimately blocks the normal
delivery to (and organization of) barrier lipids in the extracel-
lular domains of the SC.
The severe skin defects associated with ABCA12 mutations
underscore the critical role(s) for epidermal lipid transport,
especially that of GlcCer, in normal mammalian skin function.
A parallel role has been reported for the structurally-related
ABCA3 protein in the secretion of pulmonary surfactant, com-
posed primarily of phosphatidylcholine, in alveolar type II
cells [98]. The presence of ABCA3 in the limiting membrane
of lamellar bodies in these lipid-secreting lung cells [98], reveals
a common function for these related ABCA proteins in the
protection from the challenges of survival in a dry (terrestrial)
environment. Given the complex mixture of sphingolipid spe-
cies that are formed and delivered to the apical plasma mem-
brane of granular cells, additional as yet unresolved lipid
transport and sorting proteins are likely required for normal
epidermal function(s).7. Lipid processing alterations in atopic dermatitis
The contribution of SC lipid abnormalities to the pathogen-
esis of common cutaneous disorders continues to be an active
area of research. Numerous studies have linked the distinctive
barrier abnormality in patients with atopic dermatitis (AD) to
altered SC lipid content, most-notably, diminished Cer levels
[7,8,99]. Although diﬀerences in sampling and analytical meth-
ods lead to variations in the absolute levels of these reported
changes, all of these studies concur that total Cer levels are
diminished in the SC of aﬀected AD epidermis [7–9,99–101].
Fig. 3. Mechanisms for ceramide alterations in atopic dermatitis (AD). A number of possible mechanisms may account for the decreased ceramide
content noted in the SC of AD patients, including: (1) a decrease in de novo ceramide synthesis; (2) deacylase activity to generate glucosyl-
sphingosine and/or sphingosyl-phosphorylcholine; (3) increased ceramidase activity; and/or (4) decreased sphingomyelinase activity.
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ences in either GlcCerase or alkaline-ceramidase (alk-CDase)
activities in the SC from AD epidermis [102]. Subsequent stud-
ies by these same authors revealed not only high activity of a
novel enzyme with properties of a sphingomyelin deacylase
[103], but also elevated content of the unique end-product of
this enzymatic activity, sphingosyl-phosphorylcholine (SPC
or lyso-sphingomyelin) [104] (see Fig. 3). Additional studies
later demonstrated a similar GlcCer deacylase activity in AD
epidermis [105]. Since the responsible enzyme(s) has/have nei-
ther been cloned nor further identiﬁed, due in part to the
low baseline expression in normal epidermis, it remains unclear
whether this latter activity either represents a novel enzyme
[105], a single enzyme with combined GlcCer and SM deacyl-
ase activities [106], or possibly is of bacterial origin. Despite
this limitation, elevation of one-or-both of these novel enzyme
activity(ies) could explain both the diminished Cer and sphin-
gosine levels in the SC of AD patients [107] (Fig. 3, Step 2),
and thus, contribute to the barrier abnormality, as well as
other disease aspects. Indeed, sphingosyl-phosphorylcholine
(SPC), coupled with decreased sphingosine could contribute
to the increased proliferation, altered keratinization, inﬂam-
mation, and even increased tendency for secondary bacterial
infections in AD [107–109].
Interestingly, atopic SC was shown to be deﬁcient not only
in free Cer species [7,8,99–101], but also in covalently-bound
x-hydroxyCer (corneocyte-bound lipid envelope) [9]. Signiﬁ-
cant decreases in de novo synthesis of x-esteriﬁed Cer 4
(EOH), and Cer 3 (NP) also were noted in keratinocytes from
lesional skin [9] (Fig. 3, Step 1). Thus, lesional AD epidermis
contains signiﬁcant deﬁciencies of key barrier Cer species that
may contribute not only to permeability barrier alterations,
but also to other functional defects (e.g., antimicrobial) in
the skin of these patients.
At least four ceramidase (CDase) activities are present in
mammalian epidermis [110], with high alk-CDase activity re-
ported in the SC [111]. Although no alteration in alk-CDase
activity was noted in AD skin samples vs. age-matched con-
trols [102,107], reduction of acid-CDase activity is evident
[107]. Thus, the decreased sphingosine levels in involved AD
skin [107] suggest that, in addition to elevations in the novel
GlcCer/SM deacylase activities (Fig. 3, Step 2; see also above),
reduced CDase activity(ies) also could underlie this abnormal-ity (Fig. 3, Step 3). In addition, speculation continues regard-
ing possible contributions of bacterial CDase both to normal
epidermal function and to AD progression [112]. Although ele-
vated bacterial colonization correlates with the severity of ato-
pic skin lesions, an eﬀect attributed to diminished content of
the natural anti-bacterial sphingosine [107,113], the extent to
which these changes in endogenous and/or exogenous CDase
activity(ies) contribute to the pathogenesis of AD has yet to
be resolved.
Finally, contrary to the earlier studies that reported either no
signiﬁcant alterations in SMase activity in AD skin [114], or in-
creases in SMase protein levels by quantitative immunoblot
analysis [115], reductions of both aSMase and nSMase activities
have been noted in lesional AD skin [89] (Fig. 3, Step 4). In addi-
tion, the levels of prosaposin, the precursor for sphingolipid
activator proteins, and/or saposin D itself, also appear to be
diminished in psoriatic epidermis [88], suggesting yet another
potential contributing factor to altered lipid processing in the
epidermis of AD patients. Despite these contrasting ﬁndings
regarding enzyme activities that likely represent diﬀerences in
sampling and/or assay techniques, better understanding of the
relative contributions of each of the above-mentioned altera-
tions in lipid processing enzymes to the reduction in the content
of speciﬁc epidermal Cer species, and the associated permeabil-
ity barrier abnormality in AD [116,117], could reveal the most-
appropriate therapeutic (non-immune-based) approaches to this
debilitating dermatitis [118].8. Altered lipid processing in psoriasis
Not surprisingly, the severity of barrier defect in psoriatic
skin is proportional to the disease phenotype. Although a
number of studies suggest a role for altered lipid processing
in psoriasis, whether these alterations are involved in the
pathogenesis, or simply represent a consequence of this com-
plex cutaneous disorder, remains unresolved. A number of
reports cite altered Cer distribution and/or content in psoriatic
epidermis. For example, Motta and colleagues reported
decreased content of speciﬁc Cer species in psoriatic scale vs.
normal SC; i.e., Cer 1 (EOS)1 (see structures in Fig. 1), as well
as phytosphingosine-containing Cer species, Cer 3 (NP) and
Cer 6 (AP), with simultaneous increases in other Cer species,
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The contribution of altered lipid processing to these changes
in lipid content has been explored, yielding contrasting results.
An early report compared the in vitro activities of fourteen
distinct acid hydrolases in epidermal keratome samples from
eight psoriatic vs. 36 normal (non-diseased) patients [120,
121]. Signiﬁcant elevations in total b-glucosidase activity (i.e.,
11-fold over mean control values) were noted [120]. Con-
versely, diminished GlcCerase mRNA has been reported in
whole skin punch biopsies from lesional sites in ﬁve patients
with psoriasis vulgaris, when compared with skin from
healthy, non-aﬀected controls [122]. Immunohistochemical
localization (using an antibody produced against a GST-fusion
protein containing GlcCerase cloned from human skin) also
revealed a corresponding decrease in GlcCerase protein in le-
sional psoriatic epidermis [122]. Interestingly, non-lesional skin
also showed a signiﬁcant decrease in epidermal mRNA level
and immunostaining for GlcCerase vs. normal control skin,
with both of these parameters lower than in lesional skin. De-
creased immunostaining for acid-SMase in SC from lesional
vs. non-lesional psoriatic skin also has been reported [123].
These results are consistent with decreases in prosaposin
mRNA and protein levels in psoriatic lesional skin [123].
Given that individual saposin proteins are co-activator pro-
teins for both GlcCerase and SMase enzymes [84,124,125], as
well as acid-CDase activity [126], and that prosaposin-deﬁcient
animals retain GlcCer species in the SC associated with dimin-
ished permeability barrier function [78], altered GlcCer (and
SM) lipid processing could contribute to disease expression
in psoriasis.9. Summary
Studies into the metabolic activities localized within the
mammalian SC are promoting continued reevaluation of the
concept that this epidermal compartment is an inert accumula-
tion of dead (enucleate) cells surrounded by static lipid-en-
riched domains. We now appreciate that the early bricks and
mortar representation of the SC does not do full justice to
the myriad biochemical and structural alterations required to
subserve its numerous critical functions. The studies reviewed
above reveal some of the biochemical complexities required
for the normal formation and maturation of these protective
lipid domains. However, the role that these key lipid changes
play not only in orchestrating the normal corneocyte transition
between the lower and outer layers, but also in disease patho-
genesis and/or progression, remain highly fertile areas for
future study. Additionally, deﬁning the role(s) of lipid trans-
port proteins, such as ABCA12, as determinants of epidermal
lipid topology in both normal and diseased skin, represents an
exciting new research area. Thus, the study of epidermal lipi-
domics, in conjunction with transgenic/knock-out approaches,
will likely drive a continuing transformation of our concepts of
the SC as a dynamic lipid and protein environs.References
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